Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2010 Apr;107(16):277-8.
doi: 10.3238/arztebl.2010.0277. Epub 2010 Apr 23.

Drug research: marketing before evidence, sales before safety

David Klemperer
Editorial

Drug research: marketing before evidence, sales before safety

David Klemperer. Dtsch Arztebl Int. 2010 Apr.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Heres S, Davis J, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163(2):185–194. - PubMed
    1. Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig W-D, Lieb K. The financing of drug trials by pharmaceutical companies and its consequences: part 1. A qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials [Finanzierung von Arzneimittelstudien durch pharmazeutische Unternehmen und die Folgen - Teil 1: Qualitative systematische Literaturübersicht zum Einfluss auf Studienergebnisse, -protokoll und -qualität.] Dtsch Arztebl Int. 2010;107(16):279–285. - PMC - PubMed
    1. Bekelman J E, Li Y, et al. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289(4):454–465. - PubMed
    1. Ewart R, Lausen H, et al. Undisclosed changes in outcomes in randomized controlled trials: an observational study. Ann Fam Med. 2009;7(6):542–546. - PMC - PubMed
    1. Topol EJ. Failing the public health—Rofecoxib, Merck, and the FDA. N Engl J Med. 2004;351(17):1707–1709. - PubMed

MeSH terms